Qatar Study Will Test Whether a Noninvasive Scanner Can Detect Myocardial Infarction in Minutes
A new prospective cohort study in Qatar will ask a direct emergency medicine question: can a noninvasive electromagnetic scanner identify myocardial infarction quickly enough to add value at the bedside, or even compete with standard blood testing in the first hours of chest pain evaluation?
The trial, registered as NCT07926230, is not yet recruiting and is slated to enroll an estimated 200 adults who present to the emergency department with acute chest pain and suspected heart attack. Investigators at Weill Cornell Medical College in Qatar plan to compare the EDE CARDIO BIO-MAP scanner with conventional hospital testing, including cardiac troponin, creatine kinase-MB, myoglobin, B-type natriuretic peptide, and N-terminal pro-B-type natriuretic peptide.
The design is observational rather than interventional, but the clinical stakes are obvious. Emergency clinicians often work inside a narrow diagnostic window where ischemic chest pain, evolving biomarker release, and nondiagnostic early electrocardiograms can overlap. Any tool that shortens triage time without compromising accuracy could change how quickly patients move toward catheterization, admission, observation, or discharge.
The study is built around a single practical question: does the scanner identify acute myocardial injury with enough sensitivity and specificity to be credible against the current laboratory standard?
Emergency Chest Pain Diagnosis Remains a Race Against Time
Current diagnosis of myocardial infarction depends on a combination of clinical assessment, electrocardiography, and serial biomarker testing. Troponin remains the central laboratory marker, but it is still a blood test, and serial measurements are often needed because early values can be misleading.
The proposed scanner attempts to bypass that bottleneck. The device analyzes passive electromagnetic signals across a very broad frequency range and delivers a printed result in 50 milliseconds, with processing performed locally in Qatar. In theory, that kind of turnaround could help emergency teams identify patients who need urgent attention while laboratory assays are still pending.
Speed alone does not make a diagnostic test useful. Accuracy matters just as much, especially in acute coronary care where a false negative can delay reperfusion and a false positive can trigger unnecessary admission and downstream testing. The study’s primary endpoint therefore centers on sensitivity and specificity, measured against hospital laboratory results and the final clinical diagnosis documented in the medical record.
The Scanner Will Be Judged Against Standard Cardiac Biomarkers
Investigators plan to evaluate the scanner in vivo during emergency care and compare its output with standard blood tests. The primary outcome is the sensitivity and specificity of the EDE scanner for detecting myocardial infarction, using troponin and other biomarkers as the comparator set.
A second layer of analysis will examine the portable laboratory device used for immediate blood measurements. Those in vitro results will be measured against conventional hospital laboratory testing, allowing the study team to assess whether the portable platform itself can approximate standard diagnostics before the scanner is even considered.
The protocol also goes beyond simple pass-fail classification. It includes accuracy, misclassification rate, and precision for both the scanner and the portable lab. Correlation analyses will compare scanner and portable biomarker values, and logistic regression with area under the receiver operating characteristic curve will be used to assess the predictive power of individual biomarkers for myocardial infarction.
This is a sensible structure for an early diagnostic study. Acute chest pain is not a single disease; it is a syndrome with a broad differential diagnosis, and any new technology must prove it can separate infarction from the many other causes of symptoms that bring patients to the emergency department.
A 50-Millisecond Readout Raises Promise and Skepticism at Once
The technology behind the EDE CARDIO BIO-MAP is unusual enough to attract attention. The platform is described as a Class 1 device under the European Conformity marking system and is said to evaluate passive electromagnetic signals without drawing blood. It does not store patient data and is intended to generate an immediate printed report.
Such claims naturally invite scrutiny. Acute myocardial infarction is a biochemical and physiologic event, not a static electrical pattern, and the body’s biomarker kinetics are governed by tissue necrosis, vascular injury, and time from symptom onset. Any noninvasive device that aims to infer cardiac biomarkers indirectly will need to show that its signal tracks real clinical biology rather than background noise.
The protocol hints at the scientific rationale by referencing prior use of the same technology during the COVID-19 pandemic, when it reportedly detected SARS-CoV-2 with high specificity and sensitivity compared with PCR and antibody testing. Even so, a viral diagnosis and a myocardial infarction diagnosis are not interchangeable challenges. The former involves pathogen detection; the latter requires interpretation of dynamic myocardial injury and its laboratory signature.
One sentence captures the entire uncertainty: the scanner still has to prove it can read the heart, not just the signal around it.
Follow-Up Biomarkers May Clarify Early Versus Evolving Injury
Participants who undergo a second clinically indicated blood draw will repeat the scan and provide another research sample 4 to 6 hours later. That follow-up window matters because cardiac biomarkers may rise over time, and serial change can sharpen diagnostic confidence in patients who initially present early after symptom onset.
The study will examine changes in troponin T, troponin I, myoglobin, B-type natriuretic peptide, NT-proBNP, and creatine kinase-MB between the first assessment and the later sample. From a pathophysiologic standpoint, that design acknowledges a basic truth of emergency cardiology: early infarction may be biomarker-negative, while later sampling often reveals the biochemical footprint of myocardial necrosis.
Subgroup analyses by sex, age group, and symptom profile are also planned. Those comparisons could prove important because chest pain does not behave uniformly across patients, and both presentation and biomarker performance can vary with age, sex, and symptom pattern.
The study excludes pregnant adults, patients with cognitive disorders, unconscious patients, and citizens from countries where GDPR applies because of regulatory constraints. Enrollment will occur at Hamad Medical Corporation, with English and Arabic speakers eligible for participation.
What This Study Can and Cannot Answer Yet
For now, this is a diagnostic validation effort, not a results story. No performance data are available, and the scanner will not be used for clinical care during the study. Participants will not see the scanner output, and treatment decisions will remain grounded in usual emergency department evaluation.
That restraint is appropriate. A diagnostic device that acts outside the care pathway should be tested against hard clinical endpoints before anyone considers workflow adoption. The central question is whether a noninvasive readout can match, or meaningfully complement, established biomarker testing in real patients with suspected infarction.
If the scanner performs well, the appeal is straightforward: rapid triage without venipuncture, local data processing, and an immediate result at the point of care. If it performs poorly, the study will still provide a necessary boundary on what electromagnetic inference can and cannot do in acute cardiac care.
The first meaningful answer will not arrive until the estimated start date in 2027, and the primary completion date is listed for June 2029. Until then, the trial remains a hypothesis in search of proof, with sensitivity, specificity, and misclassification rate set to decide whether this device has a place in emergency myocardial infarction diagnosis or stays a fascinating but unvalidated concept.